Finally, AZD8186 improved the anticancer activity of anti-PD1 antibodies in the PTEN-deficient BP murine melanoma xenograft model, but it did not lead to improved results in the PTEN-wild-type CT26 xenograft model. Here, PTEN is linked to melanoma.